SCHEMBL1306118

SCHEMBL1306118

COC(=O)c1[nH]c2cc(Cl)c(F)cc2c1C=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.48
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
MAP2 P11137 3/20 0.41
ALPL P05186 1/20 0.39
GAA P10253 4/20 0.39
MAPT P10636 3/20 0.39
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
USP2 O75604 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PTGS1 P23219 3/20 0.38
PTGS2 P35354 3/20 0.38
TSHR P16473 3/20 0.38
LMNA P02545 2/20 0.38
PKM P14618 2/20 0.38
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26688497 0.84 MEN1 (0.51) ALOX15MEN1KMT2AGAAMAPT
SCHEMBL29955715 0.78 ALOX15 (0.74) ALOX15ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5402454 0.78 ALOX15 (0.60) ALOX15MEN1KMT2AMAP2GAA
SCHEMBL29953042 0.78 ALOX15 (0.60) ALOX15MEN1KMT2AMAP2GAA
SCHEMBL29951480 0.78 KMT2A (0.56) ALOX15MEN1KMT2AGAAMAPT
SCHEMBL29955020 0.78 MEN1 (0.61) ALOX15MEN1KMT2AGAAMAPT
SCHEMBL4400339 0.75 TUBB4A (0.48) ALOX15MEN1KMT2AMAP2ALPL
SCHEMBL25207025 0.74 ALOX15 (0.57) ALOX15MEN1KMT2AGAAMAPT
SCHEMBL5392425 0.74 ALDH1A1 (0.55) ALOX15MEN1KMT2AGAAMAPT
SCHEMBL22346709 0.73 KMT2A (0.54) ALOX15MEN1KMT2AGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8053457-B2 3-imidazolyl-indoles for the treatment of proliferative diseases NOVARTIS AG (CH) 2011-11-08 US disclosed
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases NOVARTIS AG (CH) 2010-05-20 US disclosed
EP-2142535-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis Ag (CH) 2010-01-13 EP disclosed
WO-2008119741-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases MDM4, TP53, MDM2 ALOX15 3177/4885MEN1 323/4885KMT2A 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.